<DOC>
	<DOCNO>NCT01361646</DOCNO>
	<brief_summary>This dose block-randomized , double-blind , active placebo control , single multiple dosing , dose-escalation study evaluate tolerability , safety pharmacokinetic / pharmacodynamic characteristic . Adverse event , physical examination , vital sign , ECG laboratory test conduct safety/tolerability evaluation serial blood sample urine collection pharmacokinetic pharmacodynamic evaluation conduct specified time point .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetic/Pharmacodynamic Characteristics LC350189</brief_title>
	<detailed_description />
	<mesh_term>Hyperuricemia</mesh_term>
	<criteria>1 . Healthy male subject age 20 50 year screen 2 . Subjects Body Mass Index ( BMI ) 18.0 ( inclusive ) 27.0 kg/m2 ( exclusive ) ; total body weight 55 kg ( inclusive ) 90 kg ( exclusive ) . â˜ž BMI ( kg/m2 ) = body weight ( kg ) / { height ( ) } 2 . 3 . Subject inform investigational nature study voluntarily agree participate study sign Institutional Review Board ( IRB ) approve informed consent prior perform screen procedure . 4 . Findings within range clinical acceptability medical history physical examination , laboratory result within laboratory reference range relevant laboratory test</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>